Drug Profile
Research programme: STAT4 inhibitors - Amgen
Alternative Names: Interleukin-12 inhibitors research programme - Amgen; Research programme: interleukin-12 inhibitors - Amgen; STAT4 inhibitors research programme - AmgenLatest Information Update: 27 Dec 2007
Price :
$50
*
At a glance
- Originator Tularik
- Class
- Mechanism of Action Interleukin 12 inhibitors; STAT4 transcription factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Immunological disorders
Most Recent Events
- 10 Mar 1999 Preclinical development for Immunological disorders in USA (Unknown route)